{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:25:48Z","timestamp":1794360348983,"version":"4.9.0"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase (JAK) inhibitors alleviate pruritus and clinical signs of canine atopic dermatitis (cAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To confirm the optimal dosing regimen of atinvicitinib, a second\u2010generation highly selective inhibitor of JAK1 in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Sixty\u2010one client\u2010owned dogs, \u2265\u200912\u2009months and \u2265\u20092\u2009kg, with cAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      In a randomised, masked, placebo\u2010controlled clinical trial, dogs received atinvicitinib, with food, at 0.8\u20131.2\u2009mg\/kg, once daily for 28\u2009days (q.d. group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921) or 0.4\u20130.6\u2009mg\/kg twice daily for 14\u2009days followed by once daily dosing for 14\u2009days (b.i.d.\u2013q.d. group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921); or placebo b.i.d.\u2013q.d. (control group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919). Owners assessed pruritus (Day [D]0\u20137, D14, D28) using a Visual Analog Scale (PVAS); veterinary surgeons assessed skin lesions (D0, D28) using the cAD Extent and Severity Index, 4th iteration (CADESI\u201004). On D0, D14 and D28, blood and urine samples were collected. Treatment success was defined as a \u2265\u200950% reduction from baseline PVAS or CADESI\u201004 on D28. Proportions of dogs with \u2265\u20092 PVAS reduction, and reduction in PVAS and\/or CADESI\u201004 from baseline, also were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Treatment success was 87.5% for the q.d. group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) and 73.3% for the b.i.d.\u2013q.d. group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033) (23.1% control group). There was \u2265\u20092 decrease in PVAS in 80.0% of q.d. dogs. (16.7% controls,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042). Compared to controls, atinvicitinib\u2010treated dogs had a significantly greater reduction in PVAS (q.d.,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003, b.i.d.\u2013q.d.,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and CADESI\u201004 (q.d. group,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046). Mean results of clinical pathological values remained within reference ranges. Treatment was well\u2010tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Relevance<\/jats:title>\n                    <jats:p>Once\u2010daily atinvicitinib was safe, well\u2010tolerated and effective at rapidly reducing pruritus and resolving cAD\u2010associated skin lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vde.70106","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:45:08Z","timestamp":1789692308000},"page":"916-923","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Field Safety of the Second\u2010Generation, Highly Selective\n                    <scp>JAK1<\/scp>\n                    Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo\u2010Controlled Clinical Trial in Client\u2010Owned Dogs"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6940-5771","authenticated-orcid":false,"given":"Faris","family":"Jirjis","sequence":"first","affiliation":[{"name":"Merck Animal Health  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-9857","authenticated-orcid":false,"given":"Timothy J.","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Merck Animal Health  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2346-0784","authenticated-orcid":false,"given":"Robin C.","family":"Lynn","sequence":"additional","affiliation":[{"name":"Merck Animal Health  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0119-1011","authenticated-orcid":false,"given":"Lindsey","family":"Overbey","sequence":"additional","affiliation":[{"name":"Merck Animal Health  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7104-4719","authenticated-orcid":false,"given":"Qi","family":"Cao","sequence":"additional","affiliation":[{"name":"MSD Animal Health  Boxmeer the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9054-7773","authenticated-orcid":false,"given":"Matthew","family":"Stock","sequence":"additional","affiliation":[{"name":"Merck Animal Health  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9344-6635","authenticated-orcid":false,"given":"Inka","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"MSD Animal Health  Schwabenheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2024.11.002"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12194"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13319"},{"key":"e_1_2_11_7_1","unstructured":"FDA \u201cFreedom of Information Summary for the Original Approval of NADA 141\u2013345 Apoquel (Oclacitinib Tablet) \u201d 2013 https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/902."},{"key":"e_1_2_11_8_1","unstructured":"FDA \u201cFreedom of Information Summary for the Original Approval of NADA 141\u2013585 Zenrelia (Ilunocitinib Tablet) \u201d 2024 https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/15865."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.22.12.0570"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152327"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2025.46.240113"},{"key":"e_1_2_11_12_1","first-page":"179","article-title":"The Second\u2010Generation Janus Kinase Inhibitor Atinvicitinib Is a Potent and Highly Selective Inhibitor of JAK1","volume":"37","author":"Kowalski T.","year":"2026","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_13_1","unstructured":"European Medicines Agency \u201cSummary of Product Characteristics Numelvi Atinvicitinib Tablets for Dogs. Union Product Database \u201d 2025 https:\/\/medicines.health.europa.eu\/veterinary\/en\/documents\/download\/7afee6c1\u2010cf8c\u20104386\u20108d28\u20109a2572242783."},{"issue":"17","key":"e_1_2_11_14_1","first-page":"179","article-title":"The Second\u2010Generation Janus Kinase Inhibitor Atinvicitinib Significantly Reduces Pruritus 2\u20134\u2009h After Dosing Dogs in a Canine Interleukin\u201031 Model","volume":"37","author":"Kowalski T.","year":"2026","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2007.00616.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00728.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12107"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00758.x"},{"key":"e_1_2_11_19_1","unstructured":"EMA \u201cCombined VeDDRA List of Clinical Terms for Reporting Suspected Adverse Events in Animals and Humans to Veterinary Medicinal Products \u201d 2025 https:\/\/www.ema.europa.eu\/en\/documents\/other\/combined\u2010veddra\u2010list\u2010clinical\u2010terms\u2010reportingsuspected\u2010adverse\u2010events\u2010animals\u2010humans\u2010veterinary\u2010medicinal\u2010products_en.xlsx."},{"key":"e_1_2_11_20_1","volume-title":"ATCvet Index 2026","author":"WHO Collaborating Centre for Drug Statistics Methodology"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12047"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12186"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.70009"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12984"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12682"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13134"},{"key":"e_1_2_11_27_1","first-page":"17","article-title":"The Second\u2010Generation Janus Kinase 1 Selective Inhibitor Atinvicitinib Is a Safe and Effective Once\u2010Daily Treatment for Pruritus in Dogs With Allergic Dermatitis","volume":"37","author":"Stock M.","year":"2026","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12801"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-019-1880-2"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsap.13718"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.102471"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.04.042"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01000-3"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.70106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vde.70106","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.70106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:43:22Z","timestamp":1794357802000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.70106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10.1111\/vde.70106"],"URL":"https:\/\/doi.org\/10.1111\/vde.70106","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"2026-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}